---
title: "Sana Biotechnology | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285990601.md"
datetime: "2026-05-11T20:20:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285990601.md)
  - [en](https://longbridge.com/en/news/285990601.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285990601.md)
---

# Sana Biotechnology | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.17, beating the estimate of USD -0.1725.

EBIT: As of FY2026 Q1, the actual value is USD -49.57 M.

Sana Biotechnology, Inc. operates as a single segment, and its financial and operational metrics for the three months ended March 31 are as follows:

#### Operational Performance

-   **Net Loss**: The company reported a net loss of - $47.2 million in 2026, an improvement from a net loss of - $49.4 million in 2025 .
-   **Total Operating Expenses**: Total operating expenses decreased to $48.6 million in 2026 from $50.6 million in 2025 .
    -   **Research and Development (R&D) Expenses**: R&D expenses were $28.7 million in 2026, down from $37.2 million in 2025 . This $8.5 million decrease was primarily driven by a - $4.7 million reduction in personnel-related expenses, a - $2.2 million decrease in third-party manufacturing costs, and a - $2.1 million decrease in facility and other allocated costs .
    -   **R&D Related Success Payments and Contingent Consideration**: Expenses in this category significantly increased to $8.4 million in 2026 from $2.0 million in 2025 . This change included a - $1.8 million gain related to the Cobalt Success Payment, a - $0.5 million gain for Harvard Success Payments, and a $10.7 million expense for contingent consideration .
    -   **General and Administrative (G&A) Expenses**: G&A expenses remained relatively flat at $11.5 million in 2026 compared to $11.5 million in 2025 .
-   **Interest Income, Net**: Net interest income was $1.0 million in both 2026 and 2025 .
-   **Other Income, Net**: Other income increased to $0.5 million in 2026 from $0.2 million in 2025 .

#### Cash Flow

-   **Net Cash Used in Operating Activities**: The company used - $37.4 million in operating activities in 2026, an improvement from - $48.7 million in 2025 .
-   **Net Cash Provided by Investing Activities**: Investing activities provided $49.4 million in cash in 2026, significantly up from $16.6 million in 2025, primarily due to net purchases and maturities of marketable securities .
-   **Net Cash Used in Financing Activities**: Financing activities resulted in - $0.1 million cash used in 2026, compared to $1.0 million cash provided in 2025 .

#### Liquidity and Capital Resources

-   **Cash, Cash Equivalents, and Marketable Securities**: As of March 31, 2026, Sana Biotechnology, Inc. had $101.1 million in cash, cash equivalents, and marketable securities .
-   **Accumulated Deficit**: The company reported an accumulated deficit of - $1.9 billion as of March 31, 2026 .

#### Outlook and Strategy

Sana Biotechnology, Inc. is focusing its resources on advancing key therapeutics, including SC451, SG293, and SG227, with plans to file an IND and initiate a Phase 1 clinical trial for SC451, expect initial clinical data for SG293 this year, and project clinical testing for SG227 by mid-2027 . Management has expressed substantial doubt about its ability to continue as a going concern for at least one year from March 31, 2026 . To address this, the company plans to secure additional funding through equity or debt offerings or strategic collaborations .

### Related Stocks

- [SANA.US](https://longbridge.com/en/quote/SANA.US.md)

## Related News & Research

- [Sana Biotechnology Raises $69 Million Through Equity Offering](https://longbridge.com/en/news/286614446.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)